[Standardized and Individualized Diagnosis and Treatment of Oral Squamous Cell Carcinoma: Opportunities and Challenges]

Overview

Journal Hua Xi Kou Qiang Yi Xue Za Zhi

Specialty Dentistry

Date 2020 Oct 21

PMID 33085229

Citations 1

Authors

Lai-ping Zhong

Affiliations

Soon will be listed here.

Abstract

How to improve the effects of treatment on patients with oral squamous cell carcinoma (OSCC) has always been the focus of clinical and basic studies. The standardized diagnosis and treatment of malignant tumors aim to improve the effects of treatment, and individualized treatment based on standardized diagnosis and treatment may further improve these effects. On the basis of the existing guidelines for the diagnosis and treatment of patients with OSCC, this study explored the opportunities and challenges of standardized and individualized diagnosis and treatment of OSCC. These challenges and opportunities were related to the updates of clinical and pathological staging system, surgical margins, and neck dissection in patients with OSCC at early stage and preoperative induction therapy and postoperative adjuvant treatment in patients with advanced OSCC. This study also shared ideas on clinical studies of OSCC to optimize the existing treatment schemes, improve the treatment effects, and enhance the guidelines.

Citing Articles

The prognostic value of preoperative peripheral blood inflammatory indicators for squamous cell carcinoma of tongue.

Qin S, Li C, Li R, Hu S, Li G, Sun M Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 40(3):335-340.

PMID: 38597016 PMC: 9207803. DOI: 10.7518/hxkq.2022.03.014.

References

Santosh A, Jones T, Harvey J . A review on oral cancer biomarkers: Understanding the past and learning from the present. J Cancer Res Ther. 2016; 12(2):486-92. DOI: 10.4103/0973-1482.176414. View

Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L . Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics. 2008; 7(9):1639-50. PMC: 2556024. DOI: 10.1074/mcp.M700520-MCP200. View

Ghi M, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C . Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017; 28(9):2206-2212. DOI: 10.1093/annonc/mdx299. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Andreassen C, Eriksen J, Jensen K, Hansen C, Sorensen B, Lassen P . IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncol. 2018; 86:91-99. DOI: 10.1016/j.oraloncology.2018.09.001. View

Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z . Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018; 18(1):911. PMC: 6151070. DOI: 10.1186/s12885-018-4806-7. View

Ju W, Ma H, Zhao T, Liang S, Zhu D, Wang L . Stathmin guides personalized therapy in oral squamous cell carcinoma. Cancer Sci. 2020; 111(4):1303-1313. PMC: 7156844. DOI: 10.1111/cas.14323. View

Kerawala C, Roques T, Jeannon J, Bisase B . Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S83-S89. PMC: 4873943. DOI: 10.1017/S0022215116000499. View

Chinn S, Myers J . Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol. 2015; 33(29):3269-76. PMC: 5320919. DOI: 10.1200/JCO.2015.61.2929. View

10.

Rai V, Mukherjee R, Ghosh A, Routray A, Chakraborty C . "Omics" in oral cancer: New approaches for biomarker discovery. Arch Oral Biol. 2017; 87:15-34. DOI: 10.1016/j.archoralbio.2017.12.003. View

11.

Zhong L, Zhang C, Ren G, Guo W, William Jr W, Sun J . Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2012; 31(6):744-51. PMC: 5569675. DOI: 10.1200/JCO.2012.43.8820. View

12.

Spiotto M, Jefferson G, Wenig B, Markiewicz M, Weichselbaum R, Koshy M . Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017; 143(7):691-699. PMC: 5547927. DOI: 10.1001/jamaoto.2017.0012. View

13.

Irimie A, Braicu C, Cojocneanu-Petric R, Berindan-Neagoe I, Campian R . Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics. Acta Odontol Scand. 2015; 73(3):161-8. DOI: 10.3109/00016357.2014.986754. View

14.

Zhong L, Zhang Z . Reply to K. Devisetty et al. J Clin Oncol. 2013; 31(23):2972-3. DOI: 10.1200/JCO.2013.50.4639. View

15.

Pfister D, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel D . Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(7):873-898. DOI: 10.6004/jnccn.2020.0031. View

16.

Noronha V, Joshi A, Patil V, Agarwal J, Ghosh-Laskar S, Budrukkar A . Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol. 2017; 36(11):1064-1072. DOI: 10.1200/JCO.2017.74.9457. View

17.

DCruz A, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R . Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. N Engl J Med. 2015; 373(6):521-9. DOI: 10.1056/NEJMoa1506007. View